Quick Answer
Coya Therapeutics, Inc. reported Operating Income of -$22.56 million for fiscal year 2025.
Coya Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$22.56M | -30.8% |
| 2024 | -$17.25M | -118.3% |
| 2023 | -$7.90M | +19.5% |
| 2022 | -$9.81M | -101.5% |
| 2021 | -$4.87M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.43M | +45.3% | +62.1% |
| June 30, 2025 | -$6.41M | -98.2% | +16.4% |
| March 31, 2025 | -$7.68M | -40.0% | -72.5% |
| September 30, 2024 | -$4.45M | -24.9% | -37.5% |
| June 30, 2024 | -$3.24M | +0.6% | +41.0% |
| March 31, 2024 | -$5.48M | -89.1% | -53.8% |
| September 30, 2023 | -$3.56M | -33.9% | -9.5% |
| June 30, 2023 | -$3.25M | +5.6% | -12.2% |
- Coya Therapeutics, Inc. showed a decrease of -30.8% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Coya Therapeutics, Inc.’s operating income has declined by 363.1% (from -$4.87 million to -$22.56 million).
- The most recent figure is from Coya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: